U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

Analysis by